Strain Data Sheet
Data update: Jun 20, 2019
Health Report   PCR Protocol   Thawing Method
embryos / sperm >
  Mouse Marking
RBRC No. RBRC01726  
Type Targeted MutationCartagena   wks
Species Mus musculus  
Strain name B6;129-Mfge8<tm1Osa>/OsaRbrc  
Former Common name MFG-E8 KO; MFG-E8 Knockout mouse  
H-2 Haplotype No Data  
ES cell line R1 [(129X1/SvJ x 129S1/Sv)F1-Kitl<+>]  
Donor strain (129X1/SvJ x 129S1/Sv)F1-Kitl+ via R1 ES cell line  
Background strain C57BL/6  
 1 Appearance No Data  
Genotype No Data  
Strain development Developed by Drs. Rikinari Hanayama and Shigekazu Nagata at Osaka University in 2004. A neomycin cassette replaced exons 4-6 of MFGE-8 gene. The mutant mice were backcrossed to C57BL/6N for at least 9 times.  
Strain description B6;129-Mfge8<tm1Osa>. Apoptotic cells are rapidly uptaken by macrophages. This process is essential to prevent inflammation and the autoimmune response against intracellular antigens released from dying cells. Milk fat globule epidermal growth factor 8 (MFG-E8) is a protein that specifically binds to apoptotic cells and enhance the uptake of apoptotic cells by macrophages. The MFG-E8 deficient mice developed splenomegaly and suffered from glomerulonephritis as a result of autoantibody production. MFG-E8 is considered to have a critical role in removing apoptotic B cells in spleen and lymph nodes, and its deficiency can lead to autoimmune disease.  
Colony maintenance Backcross to C57BL/6(Heterozygote x C57BL/6NCrlj)  
Health Report
Gene Details
Promoter No Data  
 1 Symbol Mfge8  
Symbol name milk fat globule-EGF factor 8 protein  
Chromosome 7  
Common name MFG-E8, Mfgm, SED1  
Symbol description No Data  
Promoter mouse phosphoglycerate kinase promoter (PGK promoter)  
 2 Symbol neo  
Symbol name neomycin resistance gene (E. coli)  
Chromosome 7  
Common name neo; neomycin;  
Symbol description No Data  
References Science. 2004 May 21;304(5674):1147-50.  
Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice.
Research applications Immunology and Inflammation Research  
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested.
Science, 304, 1147-1150 (2004).
RECIPIENT may only use the BIOLOGICAL RESOURCE for non-commercial academic research purpose.
The RECIPIENT should negotiate with the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE.
For period of two (2) years after deposition by the DEPOSITOR to the REKEN BRC, the RECIPIENT agrees to include the DEPOSITOR/DEVELOPER as a co-author.  
Additional information
 1 Lab HP  
 2 Mouse of the Month Nov 2006  
 3 Genotyping protocol <PCR>  
Depositor Nagata, Shigekazu (Graduate School of Medicine, Kyoto University)  Nagata, Shigekazu 
Strain Status /
(Expected delivery)

back Back
RIKEN BioResource Research Center

English page click here ANIMAL SEARCH SYSTEM